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Abstract
The retest effect—improvement of performance on second exposure to a task—may impede
the detection of cognitive decline in clinical trials for neurodegenerative diseases. We
assessed the impact of the retest effect in Huntington’s disease trials, and investigated its
possible neutralization. We enrolled 54 patients in the Multicentric Intracerebral Grafting in
Huntington’s Disease (MIG-HD) trial and 39 in the placebo arm of the Riluzole trial in Hunting-
ton’s Disease (RIL-HD). All were assessed with the Unified Huntington’s Disease Rating
Scale (UHDRS) plus additional cognitive tasks at baseline (A1), shortly after baseline (A2)
and one year later (A3). We used paired t-tests to analyze the retest effect between A1 and
A2. For each task of the MIG-HD study, we used a stepwise algorithm to design models pre-
dictive of patient performance at A3, which we applied to the RIL-HD trial for external valida-
tion. We observed a retest effect in most cognitive tasks. A decline in performance at one
year was detected in 3 of the 15 cognitive tasks with A1 as the baseline, and 9 of the 15
cognitive tasks with A2 as the baseline. We also included the retest effect in performance
modeling and showed that it facilitated performance prediction one year later for 14 of the 15
cognitive tasks. The retest effect maymask cognitive decline in patients with neurodegenera-
tive diseases. The dual baseline can improve clinical trial design, and better prediction should
homogenize patient groups, resulting in smaller numbers of participants being required.
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Introduction
Huntington’s disease (HD) is an inherited neurodegenerative disorder involving motor, behav-
ioral and cognitive impairments [1]. The cognitive disorders have a major impact on daily life,
but most clinical trials focus on motor endpoints. This is because clinical trial endpoints must
be able to capture both patient decline and treatment efficacy, and cognitive decline is much
more difficult to capture within one year in patients at early disease stages [2] than motor
decline. This difficulty of assessment results from the heterogeneity of cognitive changes (lan-
guage, memory, etc.) and two opposing effects: the retest effect and patient decline due to dis-
ease progression. The retest effect is defined as an improvement in performance with repeated
exposure to a task, with the greatest improvement occurring between the first two assessments
[3–5]. This effect combines familiarity with the task and testing environment and the possible
recall of responses [2]. The first assessment, during which everything is new to the patient, is
always the most difficult.
The retest effect may have contributed to the failure of some neuroprotection trials, by add-
ing noise to statistics comparing patients with different backgrounds at baseline, particularly
in trials including small numbers of patients, such as those assessing biotherapy. One
approach to neutralizing the retest effect is to carry out a second assessment (A2) shortly after
the first (A1), and then discard the results obtained at A1 from the analysis, using performance
at A2 as the baseline [2]. In addition, the retest effect (ΔA2-A1) can be used to improve the pre-
diction of long-term patient performance. Indeed, in an observational longitudinal study in
HD patients, the retest effect (ΔA2-A1 around 7 months) accounted for up to 36% of the vari-
ance of performance at A3 (ΔA3-A2 around 29 months) [6]. Likewise, in healthy elderly adults,
performance at A3 (one year) is accurately predicted by the one week-interval retest effect
(ΔA2-A1) [7].
However, the impact of the retest effect in clinical trials, which include additional variability
(placebo effect, hope, anxiety about treatment and randomization), remains unknown. Two tri-
als, theMulticentric Intracerebral Grafting in Huntington’s Disease (MIG-HD) [8] and Riluzole
in Huntington’s Disease (RIL-HD) [9] trials, were designed with a short-term test-retest proce-
dure. We used the MIG-HD trial (i) to assess whether the retest effect modified performance
and whether our strategy of using the second assessment as a baseline was sensitive to cognitive
decline in the long-term (A3) and (ii) to evaluate whether introducing the retest effect (ΔA2-
A1) into the model of disease progression in patients improved the predictive value of the
model in the long term (A3). Finally, we transferred the models obtained for the MIG-HD
cohort to the RIL-HD cohort, to assess their predictive value in another population.
Materials and Methods
Participants and design
Patients were enrolled in two separate trials: the MIG-HD trial (N = 54, Ref NCT00190450, PI
AC Bachoud-Lévi) [8], which is currently underway, and the placebo group of the cognitive
ancillary study of the RIL-HD trial conducted only in France (N = 39, Ref NCT00277602,
study coordinator Sanofi) [9]. Both trials were approved by the institutional review board
(Comité Consultatif de Protection des Personnes dans la Recherche Biomédicale) of Henri-
Mondor Hospital at Créteil (MIG-HD the September 25, 2001, and RIL-HD the December 18,
2002). Patients had signed an inform consent. The data were analyzed anonymously.
The MIG-HD trial is a phase II randomized trial assessing the efficacy of cell transplantation
in HD patients at early stages of the disease. Patients were assessed at inclusion (A1), then 35
days (SD = 15) later (A2). They were randomized at one year (A3), to determine the timing of
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transplantation (M13-M14 for the early graft group or M33-M34 for the late graft group).
Patients were followed up until 52 months.
The RIL-HD trial is a phase III multinational, randomized, placebo-controlled, double-
blind study, for which a cognitive ancillary study was conducted in France from 1999 to 2004,
on patients with moderately advanced HD. Patients were assessed at inclusion (A1), 15 days
(SD = 8) later (A2) and at one year (A3), with randomization at A2.
The demographic features for patients at A1 are displayed in Table 1.
Clinical assessments
The Unified Huntington’s Disease Rating Scale (UHDRS) [10] and additional cognitive tests
were used in both studies. Motor score reflected both voluntary and involuntary capacity and
ranged from 0 to 124 (highest severity). Functional disability was assessed with Total Func-
tional Capacity (TFC, range: 13 to 0) and Independence Scale (IS, range 100 to 0) scores, with
lower scores indicating greater functional impairment, and the Functional Assessment Scale
(FAS, 25 to 50), with higher scores indicating greater functional impairment. The severity and
frequency of behavioral dysfunctions were quantified with the behavioral part of the UHDRS
(range: 0 to 88), with higher scores indicating greater impairment. Global cognitive efficiency
was evaluated with the Mattis Dementia Rating Scale (MDRS) [11]. Several tasks were used to
assess attention and executive functions: letter fluency (for P, R and V in French) determined
for 1 minute, the Symbol Digit Modalities Test (SDMT), the three components of the Stroop
test (color naming, word reading, and color-word interference), each assessed for 45 seconds
[12], categorical fluency (for animals) assessed for 1 minute [13],[14], the Trail-Making Test
forms A and B (TMT A and B) [15], scoring the time taken to link 25 points, with a maximal
time of 240 seconds, and figure cancellation tasks [16], in which patients were asked to cross
out one, two and then three figures from a panel of signs, in 90 seconds, with lower scores indi-
cating greater cognitive impairment. Short-term and long-term memory were evaluated with
the Hopkins Verbal Learning Task (HVLT) including immediate recall, delayed recall and rec-
ognition tasks [17],[18]. By contrast to the other tasks, the HVLT was assessed with alternating
parallel forms.
Each patient performed one motor test, three functional tests, one behavioral test and 15
cognitive tests at each assessment point.
Table 1. Characteristics of patients at their inclusion (A1) in the MIG-HD and RIL-HD trials.
Characteristics MIG-HD (N = 54) RIL-HD (N = 39)
Age, y, mean (SD) 43.3 (8.7) 48.5 (10.1)
Sex % men / women 63.0 / 37.0 48.7 / 51.3
Education level, y, mean (SD) 12.0 (3.4) 12.3 (3.6)
Inheritance % paternal / maternal 60.0 / 40.0 47.6 / 52.4
Age of parent at onset, y, mean (SD) 42.2 (10.6) 45.7 (10.8)
Number of CAG repeats, mean (SD) 45.4 (4.2) 44.1 (3.6)
Time since onset, y, mean (SD) 4.5 (2.6) 6.1 (6.2)
TFC, mean (SD) 11.7 (1.0) 10.8 (1.8)
First symptom %
Motor 60.7 70.3
Cognitive 17.9 13.5
Psychiatric 21.4 16.2
y: years; SD: standard deviation; TFC: total functional capacity.
doi:10.1371/journal.pone.0145842.t001
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Statistical Analysis
Evaluation of the retest effect in the MIG-HD cohort. For each task, we used Student’s t-
tests for paired data to compare performances, first between A1 and A2, to measure the poten-
tial retest effect, then between A1 and A3, to assess the decline over a one-year period and
between A2 and A3, to determine whether discarding the A1 data unmasked a decline that was
otherwise undetectable.
Modeling of performance for the MIG-HD cohort. For each task, we selected the multi-
variate linear model best predicting the data at one year, by stepwise selection [19] with the
Akaike Information Criterion (AIC) [20]. We used an iterative algorithm (stepwise selection)
to select, without prior assumptions, the best predictive factors from a set of 10 variables (per-
formance at A1, retest, age, sex, education level expressed as the number of years spent study-
ing, parental inheritance, age of parent at disease onset, CAG repeat length, time since disease
onset and the nature of the first symptom appearing at disease onset (motor, cognitive or psy-
chiatric), as determined by the clinician or, if no clinician’s assessment was available, by the
family or the patient). Lower AIC values indicate a better fit of the model to the data. The first
model selection step was carried out for patients with complete data sets only. Estimates of
regression coefficients were refined, by recalculating each model, using all the available com-
plete data for the selected variables. The retest is the difference: performance at A2 –perfor-
mance at A1 and is denoted ΔA2-A1. For each task, performance at A3 (P) was predicted as
follows:
P ¼ b0 þ bscore at A1  performance at A1 þ bretest  DA2  A1 þ bage at A1  age
þ bsex þ beducation level  education level þ binheritance þ bage of parent at onset
 age of parent at onsetþ bCAG  CAG þ btime since onset  time since onset
þ bfirst symptom
where age, education level and age of parent at onset are expressed in years; the ﬁrst symptom
could be motor, cognitive or psychiatric; β0 is the intercept and, for each variable, βvariable is its
associated regression coefﬁcient (0 for the variables not selected). For quantitative variables,
βvariable was multiplied by the value of the variable. For qualitative variables (sex, inheritance
and ﬁrst symptom), “woman”, “maternal inheritance” and “motor symptom” constituted the
reference factors, such that βwoman = βmaternal = βmotor = 0. Calculation of the associated 95%
predictive interval (95% PI) is explained in the supplemental data (S1 Text).
External validation on the RIL-HD cohort. We used models constructed from data for
the MIG-HD cohort to predict performances at A3 for each patient in the RIL-HD cohort.
Then, for each task, we measured the concordance between observed (O) and predicted (P) val-
ues, using the intraclass correlation coefficient (ICC) and the coefficient of determination (R2e ).
The ICC was calculated with a two-way mixed effect model [21] and evaluates agreement
between observed (O) and predicted (P) performances at A3 in the RIL-HD cohort. The coefﬁ-
cient of determination (R2e ) is the percentage of the observed performance variance explained
by the model constructed from MIG-HD data. It assesses the degree to which observed perfor-
mance at A3 in the RIL-HD cohort is accurately predicted by the model, as follows:
R2e ¼ 1
X
i
ðOi  PiÞX
i
ðOi mÞ
where i refers to a patient andm is the mean observed performance at A3. R2e = 1 indicates a
The Retest Effect in Huntington's Disease
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perfect predictive value of the model, whereas R2e  0 indicates that the model is not
informative.
Analyses were performed with R 2.13 software (http://www.r-project.org/). All tests were
two-tailed and values of P< 0.05 were considered significant.
Results
Evaluating the retest effect in the MIG-HD cohort
We assessed the retest effect between A1 and A2 in the MIG-HD cohort. Performance
improved in seven cognitive tasks, and remained stable in the other cognitive, motor and func-
tional tasks, except for FAS score, which declined between A1 and A2 (Fig 1).
We assessed decline between A1 and A3 and between A2 and A3 in the MIG-HD cohort (Fig
2). The use of A2 as the baseline increased the number of tasks for which a decline in perfor-
mance was detected from three to nine, but FAS score was the only motor or functional perfor-
mance affected. Indeed, FAS performance declined between A1 and A3 but not between A2 and
A3. Behavioral performance improved between A2 and A3.
Modeling of performance in the MIG-HD cohort
Table 2 displays the regression coefficients of the predictive model for each task, for the
MIG-HD cohort. Performance at A1 was predictive of performance at A3 in all tasks. Introduc-
ing the difference in performance between A1 and A2 (ΔA2-A1) into the models improved the
prediction of performance at A3 for 14 of the 15 cognitive tasks, for behavioral and motor per-
formance and TFC. Larger numbers of CAG repeats were associated with a poorer FAS and IS
scale scores and poorer motor performance, but better behavioral performance. Women out-
performed men in 7 of the 15 cognitive tasks. Sex had no effect on motor and functional perfor-
mances, whereas behavioral performance was better in women than in men. Higher education
levels were associated with better performance at A3 for all components of the HVLT.
The regression coefficients presented in Table 2 are those used in the predictive models. For
example, the performance at A3 in letter Fluency 1’ is given by the following formula:
performance at A3 ¼
10:27þ 0:66  performance at A1 þ 0:84  retest woman
10:27þ 0:66  performance at A1 þ 0:84  retest 2:55man
(
The equations associated with the predictive models for each task are detailed in S1 Table.
Moreover, S2 Table gives additional parameters for calculation of the 95% PI.
External validation on the RIL-HD cohort
For each task, we determined the predictive value of models by calculating the ICC and R2e (Fig
3). Performance in the RIL-HD trial was well predicted for 14 of 20 tasks by the models devel-
oped with data for the MIG-HD cohort (R2e  0.5 and ICC 0.6).
Discussion
The design of clinical trials for neurodegenerative diseases could be improved by methodologi-
cal approaches based on our knowledge of the patient’s cognitive performances. However, cog-
nitive knowledge is obtained mostly through longitudinal follow-up in observational studies,
which may not include variability factors inherent to clinical trials. The retest effect may
impede observations of cognitive decline in patients with Huntington’s disease. We therefore
assessed its impact in two long-term clinical trials in HD patients, with a short interval between
The Retest Effect in Huntington's Disease
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the first and second assessments (MIG-HD, RILH-HD). We first determined whether there
was a detectable retest effect between the first two assessments (A1 and A2), and then evaluated
the impact of this effect one year later (A3). We found that replacing A1 with A2 as the baseline
unmasked a decline that would not otherwise have been detected. Indeed, the comparison
between A2 and A3 showed declines that were not apparent in the comparison between A1 and
A3. We also modeled patient performance and showed how the inclusion of the retest effect in
patient performance models would improve trial design.
At one year, decline was observed in a few cognitive tasks (SDMT, MDRS and the HVLT
immediate recall), the motor task and all functional tasks. However, consistent with previous
findings [2], there was a pronounced retest effect in cognitive tasks (letter fluency, SDMT,
Stroop color and color/word interference, TMT A and 2- and 3-figure cancellation tasks), but
no such effect in motor and functional assessments. This retest effect may hamper the objective
detection of cognitive decline, with a major impact in tasks with a high cognitive demand,
obscuring performance decline over a one-year period [22]. Neutralization of the retest effect is
particularly important in clinical trials, because some patients may already have been exposed
to testing whereas others have not, adding background noise to the overall performance data.
Assuming that the retest effect is maximal at the second assessment, the use of this assessment
as the baseline can decrease the impact of the retest effect on subsequent assessments. By dis-
carding performances at A1 and using the performance measured at A2 as the baseline, we
unmasked a decline in six tasks (Stroop color and color/word interference, recognition part of
HVLT, TMT A and 2- and 3-figure cancellation), demonstrating the efficacy of this strategy
for small samples. However, the improvement in behavioral performance [23], contrasting
Fig 1. Impact of the retest effect in the MIG-HD cohort. SDMT: Symbol Digit Modalities Test; Stroop C, W
and C/W: Stroop color, word and color/word interference; MDRS: Mattis Dementia Rating Scale; TMT A, B:
Trail-Making Test A and B; TFC: Total Functional Capacity; IS: Independence Scale; FAS: Functional
Assessment Scale. The red curve represents the baseline (reference score A1) and the blue curve shows the
mean relative score one month later (A2). The portion of the blue curve beyond the red curve indicates
performance improvement between A1 and A2. Paired t-tests, significance: * P<0.05, ** P<0.01, ***
P<0.001.
doi:10.1371/journal.pone.0145842.g001
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with the decline in other task performances, may reflect the patients’ hopes and expectations of
treatment.
The HVLT constitutes a specific case: we alternated parallel forms because of the strength of
item recall in declarative memory tasks [24]. However, alternation was not used for other tasks,
because parallel forms are of no interest for procedural tasks or tasks with a strong motor out-
put (SDMT, TMT A and verbal fluency tasks) [25]. The use of parallel forms should also be
limited because of their low intrasubject equivalence, potentially introducing noise into longi-
tudinal performance analyses. Furthermore, the ceiling effect observed in patients with high
scores in the HVLT, MDRS and TMT tasks limits the utility of neutralizing the retest effect.
However, the retest effect depends not only on the nature of the task, but also on the popula-
tion assessed [26]. Indeed, Cooper et al. [27], [28] demonstrated the existence of a retest effect
in categorical fluency assessment in healthy participants but not in patients with Alzheimer’s
disease or mild cognitive impairments. Likewise, we found no retest effect for this task in HD
patients.
In addition to masking decline, the retest effect may provide information about disease pro-
gression [7]. This suggests that combining a strategy based on the individual performance of
patients and the nature of the tasks may be useful. Indeed, the modeling of patient performance
at one year for each task showed that ΔA2-A1 performance, even in the absence of a significant
retest effect, accurately predicted performance for most cognitive tasks in HD and for motor
and behavior tasks and TFC. ΔA2-A1 performance appears to be more frequently selected by
stepwise algorithms than sociodemographic and genetic variables. We also arbitrated between
parameters to strengthen our models. For example, both the number of CAG repeats and age
Fig 2. Observed performance at one year (A3), with A1 or A2 used as the baseline, in the MIG-HD
cohort. SDMT: Symbol Digit Modalities Test; Stroop C, W and C/W: Stroop color, word and color/word
interference; MDRS: Mattis Dementia Rating Scale; TMT A, B: Trail-Making Test A and B; TFC: Total
Functional Capacity; IS: Independence Scale; FAS: Functional Assessment Scale. The red curve represents
the baseline (reference score). The blue (or green) curve corresponds to the mean relative score one year
later (A3), with A1 (or A2 for the green curve) used as the baseline. A green curve within the blue curve
indicates that the decline was easier to detect if A2 was used as the baseline, rather than A1. Paired t-tests,
significance: * P<0.05, ** P<0.01, *** P<0.001.
doi:10.1371/journal.pone.0145842.g002
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at onset are eligible variables [29], but they are correlated [30–32], so only one of these factors
should be included in the model [33]. We decided to include the number of CAG repeats, as
age at onset is subject to some degree of subjectivity. Likewise, rather than using the perfor-
mance in one task to explain performance in another task (e.g. using motor score to explain
TFC [34]), we limited the set of eligible variables to demographic variables. Finally, we did not
include handedness in our models, because 90% of the patients were right-handed.
This approach made it possible to include a larger number of covariates in our models than
in those of previous studies and to prioritize them through the selection algorithm. For exam-
ple, the number of CAG repeats has been reported to affect general verbal and spatial abilities
[35], whereas our stepwise selection suggested that it was predictive of performance in the
3-figure cancellation task, which has a spatial nonverbal component. Indeed, the number of
CAG repeats was found to have less impact than the sex of the patient in verbal tasks (letter
and categorical fluencies) and sex was not included in the model described in the previous
study. Furthermore, dichotomization of the number of CAG repeats variable (small and large
numbers of repeats) may have resulted in greater importance being assigned to this variable
than in models, such as ours, in which the number of CAG repeats was treated as a continuous
variable. Like Ruocco [36], Kieburtz [37] and Feigin et al. [38], we showed that the number of
CAG repeats improved in the prediction of motor performance, but not TFC. Finally, higher
education levels were associated with a better performance, for all HVLT components.
The small number of patients enrolled in the MIG-HD study is a potential limitation in the
search for predictive factors for future studies. However, external validation on the RIL-HD
cohort, through calculation of the intraclass correlation coefficient and the determination coef-
ficient (R2e ), demonstrated the reproducibility and robustness of our models, regardless of the
differences between the two trials. Indeed, patients in the MIG-HD trial were not randomized
until one year (A3), whereas those in the RIL-HD study were randomized at the second assess-
ment (A2). Consequently, the patients in the MIG-HD study approached the intervention with
greater hope, whereas those in the placebo group of the RIL-HD study may have been aware of
a lack of improvement during the follow-up period. This difference may account for the poor
prediction of behavioral performance in the RIL-HD study (R2e < 0). By contrast, the difference
in time interval between A1 and A2 in the two studies had no impact on prediction quality,
Fig 3. External validation of models in the RIL-HD cohort, based on Re2 and ICC. SDMT: Symbol Digit
Modalities Test; Stroop C, W and C/W: Stroop color, word and color/word interference; MDRS: Mattis
Dementia Rating Scale; TMT A, B: Trail-Making Test A and B; HVLT: Hopkins Verbal Learning Task; TFC:
Total Functional Capacity; IS: Independence Scale; FAS: Functional Assessment Scale. N: number of
patients in the RIL-HD cohort for whom all the data required for the predictive model were available. Re
2:
coefficient of determination for external validation. ICC: intraclass correlation coefficient. 95% CI: 95%
confidence interval. a: Re
2 = -0.7. The red line represents the limit for a high-quality model (Re
2 > 50% of the
observed variance explained by the model).
doi:10.1371/journal.pone.0145842.g003
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further demonstrating the validity of the models. The models were constructed with data from
patients with relatively mild disease. They may, therefore, not be applicable to patients with
more advanced HD. Indeed, retest effects would be expected to be smaller in patients with
more severe disease.
Our findings indicate that the retest effect is a limitation in clinical trials, but that both its
neutralization, through the use of a second assessment as a baseline, and its integration into
task modeling would be beneficial in future trials. For example, our predictive models may
facilitate the identification of rapid decliners [39], defined as individuals whose observed per-
formance is worse than predicted. Indeed, in longitudinal clinical trials, treatment effects could
be masked in such patients, as already shown for Alzheimer’s disease [40]. The identification of
such patients is helpful for trial design, in two ways. First, the exclusion of such patients would
probably decrease intersubject variability, making it possible to decrease sample size. Second,
rapid decliners could be uniformly allocated to the different arms of the study by stratified ran-
domization, to ensure the constitution of comparable groups, in terms of both baseline data
and disease progression.
Our findings suggest that the retest effect is detrimental, if uncontrolled, in clinical trials for
neurodegenerative diseases, such as Huntington’s disease. We show here that if two assess-
ments are performed a short time apart, use of the second assessment as the baseline increases
the chances of detecting an effect of treatment, if there is one. In addition, including the retest
effect in models renders the resulting models more predictive, making it possible to refine the
design of future trials. This constitutes a great stride forward in cognitive assessments in clini-
cal trials.
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